恆指升幅擴至近300點 首獲中金看好翰森製藥(03692.HK)三天累漲27%
恆指在國指、工商及科指分類指數升幅依次擴至2%-4.2%、以及匯控(00005.HK)和港交所(00388.HK)漲逾2.4%-2.8%帶動,現報16,899,升幅擴至286點或1.7%,總成交額855億元。
翰森製藥(03692.HK)首獲中金給予「跑贏行業」評級及目標價16元,該股反覆三連漲,午後高見14.28元,現報14.24元,續升7.9%(較上周四收市價11.18元累彈27%),但今天成交未能配合升勢僅894萬股(昨天成交增至1,740萬股)。
中金首予翰森「跑贏行業」評級及目標價16元。報告指,該公司目前已有至少6個新藥品種獲批上市,1款新藥處於上市審評階段,預計未來公司創新品種有望維持較高增速。以內地市場計,核心產品阿美樂(三代EGFR抑制劑)及孚來美(長效GLP-1)有望分別實現60億元及20億人民幣以上銷售高峰,預計公司今明兩年每股盈利分別為0.46及0.52元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.